神通胶囊治疗脑血管性痴呆30例临床观察

Clinical Observation on 30 Cases of Cerebrovascular Dementia Treated with Shen Tong Capsule

参照WHO正式公布的美国精神神经病学会脑血管痴呆(VaD)诊断标准(DSM—Ⅲ—R),选取VaD轻中度患者50例,随机分为神通胶囊治疗组30例,喜得镇(Hydergine)对照组20例。采用简短精神状况检查法(MMSE)和Blessed行为量表(BBS)于疗程前后统计分值变化进行疗效评估。结果发现,本药对VaD轻中度智能障碍核心症状及临床表现均具有治疗作用,总有效率为86.67％,治疗组MMSE和BBS表疗前疗后积分差均优于对照组,与国内外近年来同类研究比较疗效较好。

Fifty cases of mild - moderate cerebrovascular dementia selected by referring to the diagnositic criterion DSM- I -R for cerebrovascular dementia (VaD) established by America Society of Psychoneurology issued by WHO were randomly divided into Shen Tong Capsule treatment group (30 cases) and hydergine treatment group (20 cases). Modified Mental State Examination (MMSE) and Blessed Behavior Scale (BBS) were used to calculate changes of marks before and after treatment for assessment of therapeutic effects. Results show that Shen Tong Capsule has therapeutic effect on key symptoms and clinical behaviour of mild - moderate disturbance of intelligence, with the total effective rate of 86. 67%. Differences of accumulated marks in both MMSE and BBS before and after treatment in the treatment group are superior to those of the control group respectively.